Barrie

Hullmark and BGO Reveal Master Plan for Beltline Yards, A New Landmark in Toronto

Retrieved on: 
Thursday, October 12, 2023
GO Transit, Food, Partnership, BGO, Toronto Pearson International Airport, Beltline Trail, Morrison, Character, DNA, Culture, Barrie, Employment, Heart, Recreation, Line 5 Eglinton, Creativity, Caledonia station, Union Station, Life, Housing, Tourism, Industrial design, List of north–south roads in Toronto

To bring Beltline Yards to life, Hullmark and BGO have convened acclaimed international talent, including Britain's award-winning architecture and urban planning firm, Allies and Morrison.

Key Points: 
  • To bring Beltline Yards to life, Hullmark and BGO have convened acclaimed international talent, including Britain's award-winning architecture and urban planning firm, Allies and Morrison.
  • Hullmark and BGO will be drawing upon generations of expertise in designing and investing in both suburban communities and mixed-use neighbourhoods across the city to ensure that Beltline Yards reflects the spirit and values of Toronto.
  • "Through our partnership with Hullmark, we continue to shift the boundaries on innovative, thoughtful, and sustainability-driven development in Toronto.
  • "By connecting the city to the beltline with this master plan, we are creating a destination that will become a calling card for Toronto."

MediPharm Labs Announces Changes to Board of Directors

Retrieved on: 
Tuesday, December 7, 2021
SEDAR, Good, Forward-looking statement, Company, Research, API, Phrase, Failure, News, Medication, ISO, Legislation, Compliance

MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers.

Key Points: 
  • MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers.
  • Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
  • In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids.
  • Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

MediPharm Labs Completes Medical Cannabis Export to Barbados

Retrieved on: 
Friday, November 26, 2021
GMP, Patient, API, News, CEO, SEDAR, Phrase, Forward-looking statement, Company, Compliance, Medication, Health, Prescription, TSX, Legislation, OTCQX, Research, GLOBE, Marketing, ISO, Good, FSE, Failure, Medical device, Drug, Pharmaceutical industry

This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru.

Key Points: 
  • This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru.
  • BARRIE, Ontario, Nov. 26, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN).
  • Our GMP platform make us the go-to partner for companies looking to access global medical cannabis programs, said Bryan Howcroft, CEO, MediPharm Labs.
  • MediPharm Labs will continue to deliver to international jurisdictions with medical cannabis programs in place.

MediPharm Labs Expands CBN Portfolio with Two New Products

Retrieved on: 
Tuesday, November 23, 2021
GMP, Patient, API, News, CEO, SEDAR, Phrase, Forward-looking statement, Company, Medication, THC, CBD, TSX, CB1, Cannabinol, Legislation, Northbound, OTCQX, Natural health product, Research, GLOBE, ISO, CBN, Good, FSE, Failure, Cannabinoid, Fine chemical, Pharmaceutical industry

A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects.

Key Points: 
  • A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects.
  • New CBN products include CBN:CBD 1:2 Relax Formula Oil and a Northbound high CBN and high CBD vape cartridge.
  • BARRIE, Ontario, Nov. 23, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its unique cannabinol (CBN) product line.
  • This is an exciting addition to our wellness line of products which is produced to a pharmaceutical quality standard in a GMP licensed facility, said Bryan Howcroft, CEO, MediPharm Labs.

MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

Retrieved on: 
Monday, November 15, 2021
Legislation, Adjustment, Tax, News, Health Canada, Failure, SEDAR, Income, Depreciation, Phrase, ISO, International, IFRS, Research, Good, Forward-looking statement, EBITDA, Conference, Company, Analysis, Medication, Management, API, Bookkeeping

The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss).

Key Points: 
  • The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss).
  • See Reconciliation of non-IFRS measures in the Companys Managements Discussion and Analysis for the period ended September 30, 2021 for additional information.
  • Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.
  • Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

MediPharm Labs Sets Date to Report Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Legislation, News, Health Canada, FSE, OTCQX, Failure, SEDAR, Phrase, ISO, International, Good, Research, Forward-looking statement, TSX, Conference, GLOBE, Webcast, Medication, API, Animal, Internet service provider

TORONTO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release third quarter financial results for the three and nine month period ended September 30, 2021 before markets open on Monday, November 15, 2021.

Key Points: 
  • TORONTO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release third quarter financial results for the three and nine month period ended September 30, 2021 before markets open on Monday, November 15, 2021.
  • MediPharm Labs executive management team will also host a conference call and audio webcast on Monday, November 15, 2021, at 8:30 a.m. eastern time to discuss the Companys financial results and outlook.
  • A replay of the audio webcast will be available after the call has ended until November 22, 2021 11:59 p.m. eastern time.
  • Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

MediPharm Labs Appoints New Chief Executive Officer

Retrieved on: 
Thursday, October 21, 2021
Good, OTCQX, Cannabis, Research, FSE, US, Industry, Knowledge, MBA, Health Canada, TSX, Interim, Business administration, Leadership, Company, RSU, Nipissing University, CEO, Bachelor of Business Administration, API, GLOBE, ISO, Management, Fine chemical, Pharmaceutical industry

BARRIE, Ontario, Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15, 2021.

Key Points: 
  • BARRIE, Ontario, Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15, 2021.
  • Bryan Howcroft brings over 20 years of leadership in multiple industries including medical devices, healthcare imaging, and manufacturing.Most recently, Bryan held the position of Chief Operational Officer and Chief Financial Officer of Southmedic, a company that provides healthcare products, custom manufacturing, and distribution in over 60 countries globally.
  • In 2021, MediPharm Labs main growth area has been in the European markets and under the leadership of Bryan Howcroft, the Company expects to accelerate the business opportunities in that region.
  • As a pharmaceutical company specialized in precision-based cannabinoids, MediPharm Labs was seeking a CEO who could lead the charge on increased sales in the medical and consumer markets.

MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

Retrieved on: 
Tuesday, October 19, 2021
Therapeutic Goods Administration, TSX, Labs, FSE, News, Legislation, European Union, Phrase, Growth, SEDAR, Cannabis, Failure, Research, Medication, European, GLOBE, Asia-Pacific, Patient, Medicine, GMP, Drug, Partnership, Forward-looking statement, Forbes, ISO, Union, OTCQX, API, Good, Company, Pharmaceutical industry, Fine chemical

This delivery of formulated oil bottles further establishes the Companys position as a leader in the wholesale of GMP cannabis oil to the European Unions largest medical cannabis jurisdiction.

Key Points: 
  • This delivery of formulated oil bottles further establishes the Companys position as a leader in the wholesale of GMP cannabis oil to the European Unions largest medical cannabis jurisdiction.
  • The cannabis extract has been shipped to Vayamed from the Companys GMP facility located in Victoria, Australia.
  • As a pharmaceutical company specializing in precision-based cannabinoids MediPharm Labs continues to execute on delivering to its international partners.
  • All information contained in this press release with respect to Vayamed was supplied by Vayamed for inclusion herein.

With Canada’s Motorcoach Industry on the Brink of Collapse, DriverDX is the Answer

Retrieved on: 
Wednesday, September 15, 2021
Software as a service, Warner Bros. Entertainment Inc. v. RDR Books, GLOBE, Industry, Woman, Government, Transport, Tourism, News, Walking, Awareness, Road, Taxicab

If were locked down again this winter, I dont know if the industry, as a whole, can recover.

Key Points: 
  • If were locked down again this winter, I dont know if the industry, as a whole, can recover.
  • When Canada locked down, the few drivers that the industry had were sent home for over a year.
  • Being a part of the hardest hit industry, with no clear path in sight, has forced drivers to move on.
  • DriverDX also offers a unique opportunity for drivers that lost their jobs during the pandemic to leverage their unused licenses.

Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

Retrieved on: 
Tuesday, August 31, 2021
Johns Hopkins University, Company, Good, FSE, University, Legislation, Cannabinoid, Interim, McMaster, OTCQX, McMaster University, GLOBE, Letter, Research, Sleep, Cannabidiol, ISO, Insomnia, Lists of diseases, THC, Mental health, Forward-looking statement, Clinical trial, Good manufacturing practice, Safety, News, Cannabis, Patient, SEDAR, Depression, Failure, Health Canada, Phrase, TSX, API, Pharmaceutical industry, Drug

MediPharm Labs and the McMaster Research Team hope CBD50 and/or CBD10:2 provides these patients with relief from this condition.

Key Points: 
  • MediPharm Labs and the McMaster Research Team hope CBD50 and/or CBD10:2 provides these patients with relief from this condition.
  • BARRIE, Ontario, Aug. 31, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (MediPharm Labs or the Company) a pharmaceutical company specialized in cannabis, is pleased to announce that the Companys research partner McMaster University (the Researcher) has received a no objection letter from Health Canada to proceed with research with MediPharm Labs CBD50 and CBD10:2.
  • As North America has made progress in diagnosing and eliminating the stigma around mental health, more patients are looking for therapeutic treatment options.
  • As a pharmaceutical company specialized in cannabis, MediPharm Labs is encouraged by the ongoing research and development of drugs containing cannabis.